S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix

DISEASE CHARACTERISTICS: Histologically confirmed high-grade squamous intraepithelial lesions (HGSIL) of the cervix Cervical intraepithelial neoplasia (CIN) 2 (moderate dysplasia) OR CIN 3 (severe dysplasia, carcinoma in situ) Must have remaining HGSIL after biopsy No suspicion of invasive cancer by colposcopy within the past 28 days No invasive or preinvasive high-grade intraepithelial neoplasia by endocervical curettage within the past 56 days PATIENT CHARACTERISTICS: Age 18 and over Performance status Zubrod 0-1 Life expectancy Not specified Hematopoietic Not specified Hepatic SGOT and SGPT less than 2.0 times upper limit of normal (ULN) Bilirubin less than 2.0 times ULN Renal Creatinine less than 2.0 mg/dL Immunologic No prior asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs No allergy to sulfonamides No known sensitivity to celecoxib No known AIDS or HIV-associated complex Other Not pregnant or nursing Fertile patients must use effective contraception No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or adequately treated stage I or II cancer currently in complete remission PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy No prior pelvic radiotherapy Surgery See Disease Characteristics Other More than 3 months since prior topical medications for genital condyloma No prior treatment for squamous intraepithelial lesions No concurrent topical medications for genital condyloma No other concurrent treatment No concurrent chronic (daily for more than 30 days) aspirin No other concurrent nonsteroidal anti-inflammatory drugs (NSAIDs)